Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWLomefloxacin is an orally bioavailable, broad-spectrum fluoroquinolone antibiotic.1 In vitro, it inhibits growth of N. gonorrhoeae, E. coli, K. pneumoniae, P. vulgaris, S. epidermidis, and M. morganii (MIC90s = 0.1, 0.39, 0.39, 0.39, 0.39, and 0.78 μg/ml, respectively). It also inhibits growth of S. aureus and methicillin-resistant S. aureus (MRSA; MIC90 = 3.13 μg/ml for both) and of H. influenzae and ampicillin-resistant H. influenzae (MIC90 = 0.1 μg/ml for both). In vivo, lomefloxacin inhibits the growth of P. mirabilis, E. coli, K. pneumoniae, and S. aureus (ED50s = 1.39, 1.45, 1.78, and 6.66 mg/kg, respectively) in mouse models of systemic infection. It inhibits bacterial DNA gyrase, thereby inhibiting DNA synthesis and bacterial growth.2 Formulations containing lomefloxacin have been used in the treatment of bronchitis and urinary tract bacterial infections.
WARNING This product is not for human or veterinary use.
1. In vitro and in vivo activity of NY-
2. Mechanism of action of lomefloxacin. Antimicrob. Agents Chemother. 34(6), 1088-1093 (1990).